Profile
QNCX NVO VRTX REGN SGEN MRNA
Company Name Quince Therapeutics, Inc. Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. Moderna, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $44.30M $572.00B $103.88B $97.91B $43.15B $42.68B
Employees 0.03K 63.37K 5.40K 13.45K 3.26K 5.60K
CEO Dr. Dirk Thye M.D. Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Mr. Stephane Bancel
Ratings
QNCX NVO VRTX REGN SGEN MRNA
Quant Rating Score 2 5 5 5 3 4
Quant Rating Sell Strong Buy Strong Buy Strong Buy Neutral Buy
Trading
QNCX NVO VRTX REGN SGEN MRNA
Last Close $0.9934 $129.21 $402.14 $903.48 $228.74 $111.46
High 52 $1.72 $199.54 $446.08 $993.35 $228.9 $137.75
Low 52 $0.86 $87.78 $323.57 $692.45 $187.64 $69.51
Price vs. 52 Week High -42.24 % -35.25 % -9.85 % -9.05 % -0.07 % -19.09 %
Price vs. 52 Week Low 15.51 % 47.2 % 24.28 % 30.48 % 21.9 % 60.35 %
Total Return
QNCX NVO VRTX REGN SGEN MRNA
1 Month Return -5.39 % 2.17 % -1.78 % -5.36 % 0 % 7.58 %
3 Month Return -25.31 % 13.64 % -5.31 % -4.41 % 0 % 14.32 %
6 Month Return 4.57 % 28.02 % 6.8 % 10.34 % 6.49 % 56.48 %
9 Month Return -19.89 % -18.4 % 12.2 % 23.41 % 18.53 % 1.13 %
YTD Return -5.39 % 24.9 % -1.17 % 2.87 % 0 % 12.08 %
1 Year Return -36.32 % -22.72 % 16.22 % 13.15 % 14.41 % -15.18 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
QNCX NVO VRTX REGN SGEN MRNA
Dividend Yield Percentage (TTM) - 0.79 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) -114.33 % 1.54 % 13.69 % 5.88 % -3.35 % -4.41 %
Dividend Per Share (TTM) - 1.02 % - - - -
Payout Ratio (TTM) - 37.96 % - - - -
Growth
QNCX NVO VRTX REGN SGEN MRNA
Asset Growth 73.42 % 30.35 % 25.23 % 13.23 % -1.21 % -28.74 %
Gross Profit Growth -84 % 32.32 % 9.25 % 6.49 % 22.93 % -85.12 %
Revenue Growth - 31.26 % 10.17 % 7.76 % 24.65 % -64.94 %
Revenue 3 Year - 90.51 % 59.87 % 55.67 % 91.84 % 2356.27 %
Revenue 5 Year - 124.2 % 218.58 % 110.3 % 215.48 % 1070.62 %
Revenue 10 Year - 66.11 % 608.27 % 549.62 % 494.04 % 6447.35 %
EBIT Growth 52.63 % 37.11 % -12.94 % -14.6 % 10.13 % -145 %
Net Income Growth 39.25 % 50.71 % 8.96 % -8.87 % 9.51 % -156.37 %
Net Income 3 Yeari Growth Per Share 68 % 106.79 % 34.59 % 13.48 % -764.83 % -529.9 %
Net Income 5 Yeari Growth Per Share -45.59 % 133.86 % 70.33 % 74.02 % -276.93 % -160.17 %
Net Income 10 Yeari Growth Per Share -48.46 % 98.61 % 809.6 % 871.12 % -624.16 % -2046.03 %
Operating Income Growth 52.63 % 37.11 % -12.94 % -14.6 % 10.13 % -145 %
Operating Cash Flow Growth (CFG) 58.46 % 38.06 % -14.35 % -8.39 % 9.07 % -162.6 %
Operating 3 Year CFG 71.8 % 118.29 % 9.63 % 76.95 % -148.34 % -253.56 %
Operating 5 Year CFG 9.48 % 163.51 % 174.78 % 125.17 % -195.86 % -100.11 %
Operating 10 Year CFG -7.73 % 150.92 % 5187.08 % 713.56 % -2622.09 % -4698.89 %
EPS Growth 45.45 % 52.28 % 8.33 % -8.54 % 10.81 % -158.15 %
EPS Diluted Growth 45.45 % 52.37 % 8.35 % -9.03 % 10.81 % -161.39 %
Book Value Per Share -23.91 % 29 % 25.58 % 15.03 % -9.83 % -25.28 %
Share Holder 3 Year Equity Growth Per Share -61.3 % 75.22 % 104.06 % 137.56 % 33.92 % 439.94 %
Share Holder 5 Year Equity Growth Per Share -31.05 % 121.9 % 291.14 % 219.1 % 220.81 % 92.24 %
Share Holder 10 Year Equity Growth Per Share 342.81 % 49.62 % 1030.79 % 1286.9 % 691.19 % 1519.81 %
Dividend Per Share Growth - 26.89 % - - - -
Dividend 3 Year Growth Per Share - 64.4 % - - - -
Dividend 5 Year Growth Per Share - - - - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth 2949.45 % 4.74 % 44.1 % 0.06 % -23.28 % 3.58 %
Free Cash Flow Growth 58.23 % 9.17 % -16.47 % -17.11 % 3.67 % -183.5 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022 31 Dec 2023
Profitability
QNCX NVO VRTX REGN SGEN MRNA
Gross Profit Margin TTM - 84.6 % 87.21 % 87.87 % 75.4 % 31.49 %
Return on Assets TTM -17.42 % 26.61 % 15.92 % 11.95 % -20.64 % -25.58 %
Return on Equity TTM -36.36 % 90.49 % 22.62 % 16.07 % -28.06 % -29.87 %
Return on Capital Employed TTM -19.33 % 70.82 % 19.82 % 13.65 % -29.5 % -27.51 %
Net Income Per EBT TTM 99.38 % 79.95 % 82.64 % 94.15 % 101.53 % 119.58 %
EBT Per Ebit TTM 95.77 % 102.05 % 115.19 % 103.76 % 93.47 % 92.99 %
EBIT Per Revenue TTM - 44.16 % 38.53 % 30.85 % -34.37 % -61.88 %
Cash Flow To Debt Ratio TTM -135.57 % 403.27 % 437.57 % 169.97 % -475.96 % -250.84 %
Receivables Turnover TTM - 3.09 6.31 2.31 3.64 6.34
Payables Turnover TTM 0.16 1.4 3.46 2.62 2.52 9.03
Inventory Turnover TTM - 1.12 1.71 0.62 1.07 23.23
Fixed Asset Turnover TTM - 255.34 % 679.28 % 316.35 % 471.71 % 257.71 %
Asset Turnover TTM - 73.85 % 43.42 % 39.65 % 63.3 % 37.18 %
Operating Cash Flow Per Share TTM -0.45 24.39 13.73 43.1 -2.87 -8.18
Free Cash Flow Per Share TTM -0.45 15.68 12.72 35.77 -3.73 -10.04
Cash Per Share TTM 183.19 % 677.09 % 4354.48 % 10173.36 % 657.5 % 2258.27 %
Operating Cash Flow Sales Ratio TTM - 46.89 % 35.84 % 35.02 % -23.48 % -45.52 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.87 % 64.29 % 92.69 % 83.01 % 129.82 % 122.67 %
Cash Flow Coverage Ratios TTM -135.57 % 403.27 % 437.57 % 169.97 % -475.96 % -250.84 %
Price To Free Cash Flows Ratio TTM -2.4 56.91 31.68 25.68 -61.54 -11.16
Price To Operating Cash Flows Ratio TTM -2.3 36.9 29.3 20.96 -79.67 -13.62
Price Cash Flow Ratio TTM -2.3 36.9 29.3 20.96 -79.67 -13.62
Income Statement (TTM)
QNCX NVO VRTX REGN SGEN MRNA
Revenue $0B $232.26B $9.84B $13.12B $1.96B $6.75B
Gross Profit $-0B $196.5B $8.58B $11.3B $1.55B $2.06B
Gross Profit Ratio 0% 84.6% 87.17% 86.16% 79.1% 30.52%
EBITDA $-0.02B $112.94B $3.93B $5.13B $-0.62B $-3.21B
Net Income $-0.03B $83.68B $3.62B $3.95B $-0.61B $-4.71B
EPS Diluted -0.84 18.62 13.89 34.77 -3.3 -12.34
Balance Sheet (MRQ)
QNCX NVO VRTX REGN SGEN MRNA
Long Term Debt $0.01B $20.53B $0.72B $2.7B $0.04B $1.22B
Total Liabilities $0.1B $207.93B $5.15B $7.11B $0.87B $4.57B
Total Equity $0.09B $106.56B $17.58B $25.97B $2.8B $13.85B
Total Investments $0.05B $17.5B $3.45B $13.51B $1.42B $4.68B
Total Debt $0.01B $27.01B $0.81B $2.7B $0.04B $1.24B
Total Assets $0.18B $314.49B $22.73B $33.08B $3.67B $18.43B
Cash Flow Statement (TTM)
QNCX NVO VRTX REGN SGEN MRNA
Net Income $-0.03B $83.68B $3.62B $3.95B $-0.61B $-4.71B
Inventory $0B $-7.42B $-0.32B $-0.27B $-0.23B $0.75B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0.02B $108.91B $3.54B $4.59B $-0.45B $-3.12B
Capital Expenditure $-0B $-38.9B $-0.26B $-0.93B $-0.08B $-0.71B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.015
ABCL AbCellera Biologics Inc. 3.759
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 4.06
ABIO ARCA biopharma, Inc. 3.25
ABOS Acumen Pharmaceuticals, Inc. 3.32
ABSI Absci Corporation 4.98
ABUS Arbutus Biopharma Corporation 2.71
ABVC ABVC BioPharma, Inc. 1.1201
ABVX Abivax SA American Depositary Shares 14.705
ACAD ACADIA Pharmaceuticals Inc. 17.305
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 1.51
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 0.78
ACHV Achieve Life Sciences, Inc. 4.5
ACIU AC Immune SA 2.456
ACLX Arcellx, Inc. 52.93
ACRV Acrivon Therapeutics, Inc. Common Stock 8.495
ACST Acasti Pharma Inc. 2.965
ETFs With Exposure to QNCX
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 249.365
IBB iShares Biotechnology ETF 0 130.38
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 110.675
IWO iShares Russell 2000 Growth ETF 0 252.55
BIB ProShares Ultra Nasdaq Biotechnology 0 53.5199
IWC iShares Micro-Cap ETF 0.00891 114.49
BTEC Principal Healthcare Innovators ETF 0.01 35.985
IEIH iShares Evolved U.S. Innovative Healthcare ETF 0 34.1348
DFAU Dimensional US Core Equity Market ETF 0 35.0472
IBBQ Invesco Nasdaq Biotechnology ETF 0 21.49
VTSAX Vanguard Total Stock Market Index Fund 0 120.71
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0 6.19
SWTSX Schwab Total Stock Market Index Fd Select Shs a Series of Schwab Capit 0.0000503949 84.97
AVSC Avantis U.S. Small Cap Equity ETF 0 49.63
Unlock